AU2017234319A1 - Novel polysaccharide-protein conjugates and process to obtain thereof - Google Patents
Novel polysaccharide-protein conjugates and process to obtain thereof Download PDFInfo
- Publication number
- AU2017234319A1 AU2017234319A1 AU2017234319A AU2017234319A AU2017234319A1 AU 2017234319 A1 AU2017234319 A1 AU 2017234319A1 AU 2017234319 A AU2017234319 A AU 2017234319A AU 2017234319 A AU2017234319 A AU 2017234319A AU 2017234319 A1 AU2017234319 A1 AU 2017234319A1
- Authority
- AU
- Australia
- Prior art keywords
- polysaccharide
- conjugates
- protein
- protein conjugates
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 230000008569 process Effects 0.000 title claims abstract description 48
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims abstract description 33
- 150000004676 glycans Chemical class 0.000 claims description 132
- 229920001282 polysaccharide Polymers 0.000 claims description 127
- 239000005017 polysaccharide Substances 0.000 claims description 127
- 229960000814 tetanus toxoid Drugs 0.000 claims description 39
- 230000021615 conjugation Effects 0.000 claims description 37
- 102000014914 Carrier Proteins Human genes 0.000 claims description 34
- 108010078791 Carrier Proteins Proteins 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 241000588650 Neisseria meningitidis Species 0.000 claims description 21
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 230000005847 immunogenicity Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 201000009906 Meningitis Diseases 0.000 claims description 12
- 238000003556 assay Methods 0.000 claims description 12
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000000010 aprotic solvent Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 238000009826 distribution Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 150000001412 amines Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 7
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 7
- 239000001166 ammonium sulphate Substances 0.000 claims description 7
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 5
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 4
- 101710116435 Outer membrane protein Proteins 0.000 claims description 4
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 229940113088 dimethylacetamide Drugs 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 150000007942 carboxylates Chemical group 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229940125575 vaccine candidate Drugs 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 241000588653 Neisseria Species 0.000 claims 2
- 239000011369 resultant mixture Substances 0.000 claims 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- OMAHFYGHUQSIEF-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) oxalate Chemical compound O=C1CCC(=O)N1OC(=O)C(=O)ON1C(=O)CCC1=O OMAHFYGHUQSIEF-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 229940031346 monovalent vaccine Drugs 0.000 abstract description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 18
- GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical compound N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000000746 purification Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 108010060123 Conjugate Vaccines Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000005227 gel permeation chromatography Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 229940031670 conjugate vaccine Drugs 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- -1 aryl chloroformates Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000012062 aqueous buffer Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 208000037941 meningococcal disease Diseases 0.000 description 5
- 150000004804 polysaccharides Polymers 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000009013 Lowry's assay Methods 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- 206010027202 Meningitis bacterial Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 201000009904 bacterial meningitis Diseases 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 125000005587 carbonate group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- XEVRDFDBXJMZFG-UHFFFAOYSA-N carbonyl dihydrazine Chemical compound NNC(=O)NN XEVRDFDBXJMZFG-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- FHLXUWOHGKLDNF-UHFFFAOYSA-N (2-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=CC=C1OC(Cl)=O FHLXUWOHGKLDNF-UHFFFAOYSA-N 0.000 description 1
- VQKDJSXHVSAIAR-UHFFFAOYSA-N 1h-imidazol-2-yl carbamate Chemical compound NC(=O)OC1=NC=CN1 VQKDJSXHVSAIAR-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 150000007930 O-acyl isoureas Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000838698 Togo Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- NMHBKSHIKGHTFR-UHFFFAOYSA-N ethyl n-(1h-imidazol-2-yl)carbamate Chemical class CCOC(=O)NC1=NC=CN1 NMHBKSHIKGHTFR-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to novel polysaccharide-protein conjugates and process to obtain the same. More particularly, the present invention relates to polysaccharide-protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool. More specifically the present invention relates to
Description
The present invention relates to novel polysaccharide-protein conjugates and process to obtain the same. More partic ularly, the present invention relates to polysaccharide-protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool. More specifically the present invention relates to Neisseria meningitidis serogroup X, A, C, Y and W135 polysaccharide-carrier protein conjugate using carbamate chemistry and the process to obtain the same.
2017/158480
PCT/IB2017/051408
TITLE OF THE INVENTION
Novel Polysaccharide-Protein Conjugates And Process To Obtain Thereof
FIELD OF THE INVENTION
The present invention relates to novel polysaccharide-protein conjugates and process to obtain thereof. More particularly, the present invention relates to polysaccharide - protein conjugates produced using carbamate chemistry capable of being used in production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool. More specifically the present invention relates to Neisseria meningitidis serogroup X, A, C, Y and W135 polysaccharide-carrier protein conjugate using carbamate chemistry and the process to obtain the same.
BACKGROUND OF THE INVENTION
N. meningitidis (meningococcus) is an aerobic gram-negative bacterium that has been serologically classified mainly into 13 serogroups A, B, C, D, 29E, Η, I, K, L, VV135, X, Y and Z. The grouping system is based on the capsular polysaccharides of the organism. WHO official website mentions that N. meningitidis is one of the most common causes of bacterial meningitis in the world and the only bacterium capable of generating large epidemics of meningitis. Explosive epidemics with incidence rates of up to 1000 cases per 100,000 inhabitants have been reported, particularly in sub-Saharan Africa.
N. meningitidis is transmitted by aerosol or direct contact with respiratory secretions of patients or healthy human carriers. As a rule, endemic disease occurs primarily in children and adolescents, with highest attack
2017/158480
PCT/IB2017/051408 rates in infants aged 3-12 months, whereas in epidemics older children and young adults may be more involved. However, the rapid progression of meningococcal disease frequently results in death within 1-2 days after onset. N. meningitidis infections can be prevented by vaccination.
Haemophilus influenzae type b is a Gram-negative bacterium that causes meningitis and acute respiratory infections, mainly in children. The WHO official website mentions that in both developed and developing countries, it is an important cause of non-epidemic meningitis in young children, and is frequently associated with severe neurological squeal, even if antibiotics are given promptly.
Haemophilus influenzae infection is transmitted by droplets from infected (but not necessarily symptomatic) people. H. influenzae type b infections can be prevented by vaccination.
Majority of meningococcal diseases are caused by 6 serogroups viz., A, B, C, Y, W135 and X. Historically, the majority of the cases in the meningitis belt are caused by serogroup A meningococci. Serogroup C meningococci were responsible for outbreaks in the meningitis belt in the 1980s, and a new outbreak was also experienced in Niger in 2015, while serogroup W (formerly W-135) has emerged as a cause of epidemic meningitis since 2000. Serogroup Y prevalence is minimal in Africa; however, the serogroup is more evident in meningitis cases in South America. According to one NCBI publication, Serogroup X meningococci have previously been considered a rare cause of sporadic meningitis, but during 2006-2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya, Togo and Burkina Faso, the latter with at least 1300 cases
2017/158480
PCT/IB2017/051408 of serogroup X meningitis among the 6732 reported cases.
According to another NCBI publication, in Togo during 2006-2009, serogroup X meningococci accounted for 16% of the 702 confirmed bacterial meningitis cases. Kozah district experienced a serogroup X meningococci outbreak in March 2007 with a serogroup X meningococci seasonal cumulative incidence of 33/100,000. In Burkina Faso during 20072010, serogroup X meningococci accounted for 7% of the 778 confirmed bacterial meningitis cases, with an increase from 2009 to 2010 (4% to 35% of all confirmed cases, respectively). In 2010, serogroup X meningococci epidemics occurred in northern and central regions of Burkina Faso; the highest district cumulative incidence of serogroup X meningococci was estimated as 130/100,000 during March-April.
Based on the above facts, a pentavalent ACYWX polysaccharide-protein conjugate vaccine could offer broader coverage against meningococcal disease except serogroup B. Immunization is the only rational approach to control the meningococcal disease. Currently, various monovalent or multivalent vaccines including serogroup A, C, Y and W135 polysaccharide conjugates are licensed for sale in market, but no licensed vaccine is available against serogroup X meningococci. The serogroup X polysaccharide protein conjugates will be the new addition to multivalent meningococcal conjugate vaccine development in case of public health need.
Several studies suggest that the size of saccharide moiety can influence the immunogenicity of conjugate vaccines. Initial studies on the immunogenicity of dextran-protein conjugates found that dextran of low
2017/158480
PCT/IB2017/051408 molecular weight conjugated to chicken serum albumin, induced strong anti-dextran responses in mice, while increasing the dextran size resulted in reduced immunogenicity. Laferriere et al. found little influence of the carbohydrate chain length on the immunogenicity of pneumococcal conjugate vaccines in mice. These studies suggest that there is no clear correlation between polysaccharide chain length and immunogenicity of conjugate vaccine. However, Rana et al. found it important, to establish the optimum saccharide chain length for developing immunogenic Hib polysaccharide conjugate vaccine.
The reaction of the polysaccharides with the CDI has been shown in several literature references. The Carbonyldiimidazole, a particularly preferred reagent, reacts with the hydroxyl groups to form imidazolylurethanes of the polysaccharide, and aryl chloroformates, including, for example, nitrophenyl- chloroformate, producing mixed carbonates of the polysaccharide. In each case, the resulting activated polysaccharide is very susceptible to nucleophilic reagents, such as amines, and is thereby transformed into the respective urethanes.
For any conjugation chemistry the polysaccharide structure plays a very significant role. The chemistry of choice for conjugating any polysaccharide to a carrier protein depends upon the available functional groups on that polysaccharide. While some polysaccharides contain chemical groups which can be conveniently utilized for conjugation e.g. amines, carboxyls or aldehydes, many ones require activation and derivatization before they can be coupled to proteins. As evident in the literature the polysaccharide protein conjugate vaccines can be made with or without a linker, wherein the linker can be a part of polysaccharide or
2017/158480
PCT/IB2017/051408 can be attached to a carrier protein.
The existing state of art discloses vaccines for the treatment of various serogroups including Neisseria meningitidis serogroup A, B, C, W and Y such as the US patent application no US2015/0044253 which discloses the immunogenic composition comprising a saccharide fragment obtained from H. influenzae serotype B (Hib), N. meningitidis serogroup A, B, C, W, Y conjugated with a carrier protein. However, in the US2015/0044253, the carbamate linker is linked directly onto amino groups of the carrier protein which results into low conjugation efficiency.
W02004/019992 also discloses modified capsular saccharide, and saccharide protein conjugates for N. meningitidis serogroup A obtained by reductive amination, however, the application talks about the serogroup A only.
There are a few disclosures available on N. meningitidis serogroup X such as WO2013/174832 which discloses conjugate of N. meningitidis serogroup X obtained by reductive amination conjugation chemistry.
The major drawback in the existing state of art disclosures is that none of the prior arts using carbamate chemistry disclose the dissolution of polysaccharide into organic solvent to facilitate the conjugation process. The conjugates presently available suffer from stability issues. More specifically, the stable and commercially viable conjugates for N. meningitidis serogroup X are not available.
2017/158480
PCT/IB2017/051408
OBTECT OF THE INVENTION
In order to obviate the drawbacks in the existing state of art, the main object of present invention is to provide novel polysaccharide-protein conjugates.
Another object of the present invention is to provide stable polysaccharide - protein conjugates capable of being used for the preparation of novel conjugate vaccines.
Yet another object of the present invention is to provide a N. meningitidis serogroup X polysaccharide-carrier protein conjugate to expand higher coverage of the meningococcal disease incidence prevented by currently licensed vaccines.
Yet another object of the present invention is to provide a process to obtain said novel polysaccharide-protein conjugates.
Yet another object of the present invention is to provide a process to obtain said novel polysaccharide-protein conjugates using carbamate chemistry.
Yet another object of the present invention is to provide a process of rapid solubilization of the polysaccharide in non-aqueous aprotic solvents.
Yet another object of the present invention is to carry out the conjugation reaction in broader pH range.
Yet another object of the present invention is to complete the conjugation process in very short time span with high yields.
2017/158480
PCT/IB2017/051408
Yet another object of the present invention is to obtain novel polysaccharide-protein conjugates with high immunogenicity capable of being used in vaccine and as diagnostic tool.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides novel polysaccharide (PS)protein conjugates and process to obtain thereof. More particularly, the present invention relates to obtain the polysaccharide - protein conjugates by carbamate chemistry for the preparation of novel conjugate vaccines. More specifically the present invention relates to N. meningitidis serogroup X, A, C, Y and W135 polysaccharide-carrier protein conjugate using carbamate chemistry and the process to obtain the same.
The present invention relates to the process of conjugation wherein capsular polysaccharide is degraded to smaller sizes suitable for conjugation with carrier protein to obtain conjugates with higher antigenicity.
The carrier protein is selected from TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles) or other suitable carrier protein. The polysaccharide fragment is obtained from group of gram negative bacteria, including but not limited to Haemophilus influenzae type b (Hib), Neisseria meningitidis (Men), Streptococcus pneumoniae.
The process of conjugation of Neisseria meningitidis capsular polysaccharide, more preferably Men A, C, Y, W or X capsular
2017/158480
PCT/IB2017/051408 polysaccharide is degraded. Such degradation is carried out by using several techniques available in the prior art. More preferably, the degradation is carried out by probe sonication and/ or ultra-sonication at a lab scale and by micro fluidizer at larger scales. The native N. meningitidis capsular polysaccharide is degraded in the size range of distribution coefficient of 0.38+0.06 kD as determined by gel-permeation chromatography (GPC) on high performance liquid chromatography (HPLC).
After the degradation process, said degraded polysaccharide is dissolved in strong electrolytic salts for counter ion exchange, including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates. The solution is allowed for proper mixing for 60 ± 30 minutes. Moisture is removed from the resultant capsular polysaccharide by any drying technique such as rotary-evaporation. The dried capsular polysaccharide is then dissolved in the non-aqueous aprotic solvents including but not limited to anhydrous Dimethyl sulfoxide (DMSO), Dimethyl formamide (DMF), N-Methyl pyrrolidone (NMP) or Dimethyl Acetamide. Said degraded and dried capsular polysaccharide in the non-aqueous aprotic solvent is reacted with 5-50 molar excess concentration of moisture free activating agents including but not limited to Ν,Ν'-Carbonyl Di imidazole (CDI), N,N'-Disuccinimidyl carbonate (DSC) or N,N'-Di-succinimidyl oxalate (DSO) and the mixture is kept in the presence of 4-dimethylaminopyridine (DMAP) or pyridine for pre-determined time to complete the reaction.
The resultant activated capsular polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent
2017/158480
PCT/IB2017/051408 including but not limited to ethyl acetate, dichloromethane, n-butyl acetate or their mixture in different proportions, followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
The purified activated capsular polysaccharide so obtained is dissolved in aqueous buffer with an activated carrier protein. The activated carrier protein may be Carbohydrazide labelled or ADH labelled or Hydrazine labelled.
The solution of purified activated capsular polysaccharide and activated carrier protein is allowed for mixing at room temperature for predetermined period of time, preferably 15 ± 5 hours at different pH range depending on whether the said polysaccharide is CDI activated, DSC activated or DSO activated. The pH range for CDI activated polysaccharide is from 8-10, while the pH range for DSC activated or DSO activated polysaccharide is from 6-9. During this reaction the amine of the hydrazide moiety on the protein and -N- containing aromatic residue of carbamate or carbonate moiety on the activated polysaccharide reacts and results in the formation of polysaccharide-protein conjugate with stable carbamate linkage -O- (C=O)-N-. Hence the final conjugate with the formula PS-L1-L2-CR is produced, wherein PS is the polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is the carrier protein. The purified conjugates are obtained by the purification process including but not limited to ultrafiltration, ammonium sulphate precipitation, gel permeation chromatography.
The present invention also discloses the attaching of one linker preferably carbamate to the polysaccharide and second linker preferably hydrazine
2017/158480
PCT/IB2017/051408 to the carrier protein, followed by reaction of activated polysaccharide and activated protein having separate linkers to generate a conjugate.
The present improved process of conjugation completes in shorter time span and yields conjugates of more stable covalent bond at wide working range of pH. The novel polysaccharide-protein conjugate of the present invention displays more stability, high yield and high immunogenicity.
The present invention also discloses the method of dissolution of the polysaccharide in the non-aqueous aprotic solvent which facilitates conjugation reaction between the polysaccharide and the carbamate forming agent to complete the conjugation process in shorter time span.
The most significant outcome of the improved process of present invention is to provide novel polysaccharide-protein conjugates capable of being used in vaccine or as diagnostic tool. The said novel polysaccharideprotein conjugate elicit specific and homologous immune response and is therefore useful in the production of monovalent vaccine or multivalent combination vaccines as well as a diagnostic tool.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts the EDC (carbodiimide) cross-linking reaction scheme (RNH2 is either Hydrazine (H2N-NH2) or Adipic Acid Dihydrazide (ADH) (NH2NHCO(CH2)4CONHNH2).
Figure 2 depicts the monomer unit of Men X capsular polysaccharidechemical structure.
Figure 3 depicts the HPLC-SEC profile showing the elution volume on TSKgel PWXL5000 - PWXL4000 column at a flow rate of
2017/158480
PCT/IB2017/051408 lml/min showing Void volume, Total volume and Sample elution volume.
Figure 4 depicts the HPLC-SEC profile comparison of native MenX polysaccharide with sized polysaccharides.
Figure 5 depicts the HPLC-SEC profile comparison of hydrazine derivatized TT with native TT.
Figure 6 depicts the Chromatogram showing purification of hydrazide derivatized TT on sephadex G25.
Figure 7 depicts the Complete Carbamate Conjugation Scheme.
Figure 8 depicts the HPLC-SEC profile comparison of hydrazine derivatized TT with crude Men X Conjugate.
DETAILED DESCRIPTION OF THE INVENTION WITH
ILLUSTRATIONS AND EXAMPLES
The present invention provides novel polysaccharide-protein conjugates and process to obtain thereof. More particularly, the present invention relates to obtain the chemically stable polysaccharide - protein conjugates by carbamate chemistry. The polysaccharide fragment is obtained from group of gram negative bacteria, including but not limited to Haemophilus influenzae type b (Hib), Neisseria meningitidis (Men), Streptococcus pneumoniae, more preferably, N. meningitidis serogroups Men A, C, Y, W and preferably Men X. The present invention also relates to obtain novel polysaccharide-protein conjugates with high immunogenicity capable of being used in vaccine individually or in combinations or as diagnostic tool.
The present invention also relates to the process of conjugation wherein said capsular polysaccharide is degraded to smaller sizes suitable for
2017/158480
PCT/IB2017/051408 conjugation with carrier protein to obtain conjugates with higher antigenicity.
The present invention provides a process of conjugation using the CDI for hydroxyl group activation to form a polysaccharide-protein conjugates by a carbamate chemistry.
The carrier protein is selected from TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles) or other suitable carrier protein.
Said capsular polysaccharide is degraded by using several techniques available in the prior art. More preferably, the degradation is carried out by probe sonication and/or ultia-sonication at a lab scale and by micro fluidizer at larger scales. The native Neisseria meningitidis capsular polysaccharide is degraded in the size range of distribution coefficient of 0.38+0.06 kD. The size of polysaccharide is determined by gel-permeation chromatography (GPC) on high performance liquid chromatography (HPLC).
After the degradation process, said degraded polysaccharide is dissolved in strong electrolytic salts for counter ion exchange, including but not limited to Lithium halides, Lithium chloride and Quaternary ammonium halide hydrates. The solution is allowed for proper mixing for 60±30 minutes. Moisture is removed from the resultant capsular polysaccharide by any drying technique such as rotary-evaporation. The dried capsular polysaccharide is then dissolved in the non-aqueous aprotic solvents including but not limited to anhydrous Dimethyl sulfoxide (DMSO),
2017/158480
PCT/IB2017/051408
Dimethyl formamide (DMF), N-Methyl pyrrolidone (NMP) or Dimethyl Acetamide. Said degraded and dried capsular polysaccharide in the nonaqueous aprotic solvent is reacted with 5-50 molar excess concentration of moisture free activating agents including but not limited to N,N'Carbonyl Di imidazole (CDI), N,N'-Di-succinimidyl carbonate (DSC) or N,N'-Di-succinimidyl oxalate (DSO) and the mixture is kept in the presence of 4-dimethylaminopyridine (DMAP) or pyridine for predetermined time to complete the reaction. The Men PS has free hydroxyl group in its repeating unit, which when reacted to Carbonyl-diimidazole (CDI) forms an intermediate imidazolyl carbamate and imidazole byproduct.
The resultant activated capsular polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent including but not limited to ethyl acetate, dichloromethane, n-butyl acetate or their mixture in different proportions, followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
The carrier protein is reacted with water soluble carbodiimide EDC (N-(3Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride) in the presence of Hydrazine or ADH to yield stable imide bonds with extending terminal hydrazide groups. The EDC reacts with available carboxylate groups to form an intermediate, highly reactive, o-acylisourea. This active ester may further react with nucleophiles such as hydrazide to yield a stable final product (Fig 1). The EDC cross-linking scheme (R-NH2) is either hydrazine or ADH.
2017/158480
PCT/IB2017/051408
Carbonyls react with hydrazides and amines at pH 5-7. The hydrolysis of EDC is a competing reaction during coupling and is dependent on temperature, pH and buffer composition. The 4-Morpholinoethanesulfonic acid (MES) is an effective carbodiimide reaction buffer. Phosphate buffers reduce the reaction efficiency of the EDC, but increasing the amount of EDC can compensate for the reduced efficiency. Tris, glycine and acetate buffers may not be used as conjugation buffers.
The hydrazides labeling on TT is determined by TNBS assay; and the protein concentration is determined by Lowry's assay. The degree of derivatization is calculated by dividing the moles of hydrazides generated by moles of protein.
The purified activated capsular polysaccharide so obtained is dissolved in aqueous buffer with an activated carrier protein. The activated carrier protein may be Carbohydrazide labelled or ADH labelled or Hydrazine labelled.
The solution of purified activated capsular polysaccharide and activated carrier protein is allowed for mixing at room temperature for 15 ± 5 hours at different pH range depending on whether the said polysaccharide is CDI activated, DSC activated or DSO activated. The pH range for CDI activated polysaccharide is from 8-10, while the pH range for DSC activated or DSO activated polysaccharide is from 6-9. During this reaction the amine of the hydrazide moiety on the protein and -Ncontaining aromatic residue of carbamate or carbonate moiety on the activated polysaccharide reacts and results in the formation of polysaccharide-protein conjugate with stable carbamate linkage -O14
2017/158480
PCT/IB2017/051408 (C=O)-N-. Hence the final conjugate with the formula PS-L1-L2-CR is produced, wherein PS is the polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is the carrier protein. The purified conjugates are obtained by the purification process including but not limited to ultrafiltration, ammonium sulphate precipitation, gel permeation chromatography.
The conjugates prepared using carbamate chemistry has been tested to determine polysaccharide/protein ratio, amount of free polysaccharide in the conjugates and molecular size distribution. In this invention various optimization experiments have been conducted to attain the polysaccharide/protein ratio in the range from 0.30 to 1.0 and the conjugation yields of upto 60% with an average of 30±5%.
In one preferred embodiment, the Men PS derived from bacterial fermentation is purified by the downstream purification process and analyzed after purification for all the critical quality parameters. The chemical structure of Men PS consists of repeating units with free hydroxyl group(s) e.g. MenX PS (Fig. 2) consists of repeat unit having a phosphate backbone and N-acetylation at position 3. The hydroxyl groups at position no. 4 and 7 act as reactive functional groups for conjugation with carbamate inducing chemicals like CDI. The monomer repeat units are called as monosaccharides and the long chain formed by a covalent bond in-between monosaccharide units, constitutes the Polysaccharide. The monosaccharide type is specific for specific serogroup (Table 1).
Tablel: Chemical structure of capsular polysaccharides of different N. meningitidis serogroups
WO 2017/158480
PCT/IB2017/051408
| Group | Repeating unit |
| X | ^4)-D-GlcpNAc-a-(l^OPO3^ |
| A | —>6)-D-ManpNAc(3/4OAc)-a-(l—>OPO3—> |
| C | —>9)-D-Neup5Ac(7/8OAc)-a-(2—> |
| Y | —>4)-D-Neup5Ac(7/9OAc)-a-(2—>6)-D-Glc-a-(l—> |
| W | —>4)-D-Neup5Ac(7/9OAc)-a-(2—>6)-D-Gal-a-(l—> |
The native Men PS have size range of distribution coefficient of 0.38+0.06 kD as determined by SEC on HPLC using pullulan standards. The Carbamate chemistry of the present invention and the polysaccharide structure contributes for the formation of stable polysaccharide -protein conjugates to be used as a vaccine candidate either alone or in combination.
The content of degraded polysaccharide have been determined by physico10 chemical assays e.g. phosphorus assay for MenX and MenA, and have been found to be similar to that of the initial polysaccharide content.
Different experiments have been conducted to optimize and attain the distribution coefficient to an optimum range of 0.38+0.06 kD. The variable conditions have been used for he conditions varies for different batches depending upon the initial molecular size and structure of individual polysaccharide.
In one preferred embodiment, MenX Polysaccharide is degraded to smaller sizes suitable for conjugation with carrier protein to obtain conjugates with high antigenicity. Tetanus toxoid (TT) is used as carrier protein. Said degraded MenX polysaccharide is dissolved in Lithium
2017/158480
PCT/IB2017/051408 chloride. The solution is allowed for proper mixing for a duration of 60 ± 30 minutes. Moisture is removed from the resultant capsular polysaccharide by any known drying technique such as rotaryevaporation. The degraded and dried capsular polysaccharide is then dissolved in anhydrous Dimethyl sulfoxide (DMSO). The dried capsular polysaccharide in the non-aqueous aprotic solvent is reacted with 5-50 molar excess preferably 30 molar excess concentration of activating agent
N, N'-Carbonyl Di imidazole (CDI), and the mixture is kept for mixing for a period of 2 hrs to 3 hrs to complete the reaction. The pH of the reaction mixture is maintained at 7-10 preferably at 9.0. The resultant activated MenX polysaccharide is purified by precipitating the polysaccharide in an excess of low polarity solvent ethyl acetate followed by dissolving the precipitated polysaccharide in an aqueous buffer saline to obtain purified activated capsular polysaccharide.
In an another preferred embodiment the linker is hydrazine or its derivative, attached to the carrier protein. The sized active polysaccharide and the derivatized carrier protein are mixed in a proportion of 0.5:1 to 1:0.5 w/w more preferably 1:1 w/w in a buffer of pH 7.0-10.0 preferably
O. 1M Sodium carbonate,01M NaCI, pH 9.0. During this reaction the amine of the hydrazide moiety on the protein and -N- containing aromatic residue of carbamate or carbonate moiety on the activated polysaccharide reacts and results in the formation of polysaccharideprotein conjugate with very stable carbamate linkage -O- (C=O)-NThe said conjugate is purified by known techniques and analyzed for total polysaccharide content, protein content, free polysaccharide, polysaccharide-protein ratio and conjugation yield. The purified conjugates are stored 2 to 8°C.
2017/158480
PCT/IB2017/051408
The conjugates of the present invention are stable when exposed to high temperature conditions of 37°C. Men conjugates of the present invention show high antigenicity and high immunogenicity as revealed by serum bactericidal assay (SBA) and various immunogenic assays such as ELISA.
NON-LIMITING EXAMPLES
Example 1: Sizing of the Men X Polysaccharide:
200mg of Men X Polysaccharide is taken in a concentration at 10mg/ml in glass beaker on ice bath. Run the sonicator at 20% amplitude for a time of 3 hrs. The size of the degraded Polysaccharide is determined in terms of distribution coefficient (Kd) by running on HP-GPC (Table 2) using refractive index (RI) detector. Samples are eluted in 0.1 M NaNO3 at pH 7.2 in isocratic mode on TSK gel G5000 PWXL + G4000 PWXL column in series. Elution volumes are measured in terms of retention time. Void volume (Vo) of the column is calculated from the high molecular weight dextran injection retention time and the total volume (Vt) of the column is determined by sodium azide injection retention time respectively. Kd is calculated from the formulae Kd=(Ve-Vo/Vt-Vo). Ve is the retention time (RT) of elution volume of the sample (Fig. 3). The data recorded using RI detector shows the shift in peak towards right suggesting depolymerisation of native polysaccharides (Fig. 4).
Table 2: Results showing size distribution of meningococcal polysaccharide serogroup X by HP-SEC on TSK gel G5000 PWXL + G4000 PWXL column.
| Average | Polysaccharide | Time of size | RT of peak | Final | sized PS | |
| size of | co neen Ira Lion | reduction aL | HPSEC | distribution coefficient | ||
| native | 20 i> amplitude | liil | RI | ΙΒΙΙΙΙΙΙ |
WO 2017/158480
PCT/IB2017/051408
| polysdceh aride | deleclor | (Vo= 10.729m in V 1=22.801 min) | ||
| 492kDa | 200mg/20ml | 3.0hrs | 15.365 min | 0.384 Kd |
| 570kDa | 200mg/20ml | 4.5hrs | 15.322 min | 0.380 Kd |
Example 2: Polysaccharide activation with CDI
200 mg of sized polysaccharide and LiCl are mixed with slow stirring at RT for 1 hr and thereafter has been dried on rotavapour at 40°C. Then redissolved in 15 ml of dry DMSO and keep mixing for 2 hrs. 30X molar of Carbonyl di-imidazole (CDI) to polysaccharide is added then. pH has been adjusted to 9.0 by adding Triethylamine (TEA). Slow stirring done at RT for 2 hours and cool the sample in ice to stop the reaction. Added Ethyl acetate and removed the supernatant from the top. Again added Ethyl acetate and removed the supernatant from the top. Dry on high vacuum for 30 minutes.
Example 3: TT activation
250 mg TT is concentrated using 50 kDa molecular weight cut off (MWCO) centrifugal filter to make final 10 ml. The 2.75ml of Hydrazine monohydrate from stock 5 M or 2.5gm of ADH, equivalent to 10X by weight of TT is added to 10 ml of reaction buffer i.e 0.15 M MES buffer containing 0.2 M NaCl, pH 5.75 and added to TT above. To this mixture, an equal amount of EDAC (250mg) in 1ml of reaction buffer to make final concentration of approximate 30mM. The pH of the reaction mixture adjusted to 5.85 and final volume of the reaction mixture adjusted to 25 ml. The concentration of TT in reaction mixture is 10 mg/ml. The reaction mixture kept for slow stirring for 1.0 hour in ice bath. The derivatized TT is further purified and analyzed for degree of activation and SEC-HPLC to
2017/158480
PCT/IB2017/051408 monitor peak profile. HPLC-SEC profile comparison of Hydrazine activated TT with native TT is shown in Fig 5 wherein the samples have been run on chromatography column in isocratic mode and the data have been recorded using PDA detector.
Example 4: Purification of activated TT
Purification is one of the most important steps in the process and in TT activation. We need to be sure to get rid of any un-reacted hydrazine or ADH to maximum possible. The purification is done by Sephadex G-25 desalting method. Desalt the reaction mixture on sephadex G25 column against 50 mM phosphate buffer containing 75 mM NaCl, pH 7.5 to purify the derivatized protein. Chromatography column equilibrated with 50 mM phosphate buffer containing 75 mM NaCl, pH 7.5, followed by sample loading and elution at 110 cm/hr. Eluted fractions of 10 ml each collected and fractions corresponding to the peak at 280 nM on UV (Fig. 6) are pooled and concentrated by 50 kDa MWCO Amikon membrane. Selected fractions having TT are concentrated to such a volume to have TT concentration approximately 30-50 mg/ml (considering approximately 75% recovery of activated TT after desalting). Final activated TT is analyzed for protein concentration by Lowry assay and hydrazide labeling by TNBS assay. Both the values used for the calculation of degree of activation (DOA) of TT. Activated TT is run on HPLC at a concentration of 1 mg/ml using PWXL 5000 - PWXL 4000 columns in series to check the peak profile for its integrity.
The process of present invention activates the hydroxyl groups of the different polysaccharides preferably MenX PS with different activating agents preferably carbonyl di-imidazole to make it reactive towards the carrier protein to form a stable PS-TT conjugate (Fig 7).
2017/158480
PCT/IB2017/051408
Example 5: Conjugation reaction of activated MenX and derivatized TT
Derivatized TT has been added to the activated Men X PS directly in 3ml of 0.1M Sodium carbonate, 0.1M NaCl buffer at pH 9.0 solution and maintains the pH at 9.0. Activated Polysaccharide and derivatized TT are mixed in a proportion of 1:1 w/ w for the conjugation reaction. Formation of conjugate is confirmed in three hours of time only, but the crude conjugate mixture is kept mixing overnight at room temperature. The reaction is then quenched by using a 5-10 molar excess of amine-containing reagent such as glycine.
The course of conjugation is monitored by SEC-HPLC analysis with change in the retention time of the activated TT and peak shift towards the left. HPLC-SEC profile of the conjugate depicts that conjugation reaction is completed to maximum within three to four hours. The SEC-HPLC profiles of native and activated TT and the conjugate indicates that upon activation, the size of activated TT remains unchanged from the native TT, suggesting that little or no aggregation occurs. The samples have been run on chromatography column at the flow rate of 1.0 ml/min using 0.1M sodium nitrate, pH 7.2 buffer in isocratic mode and the data have been recorded using PDA detector. After conjugation, high molecular weight peak appears to the left of derivatized TT peak, indicating the formation of PSTT conjugates (Fig. 8).
Example 6: Removal of unreacted (free) Polysaccharide from crude conjugate by Ammonium sulphate precipitation
Further, crude conjugate is purified by protein precipitation method to remove free or unreacted polysaccharide. Purification is carried out by
2017/158480
PCT/IB2017/051408 slowly adding solid ammonium sulphate to the reaction mixture until conjugate is precipitated out of the solution. The precipitates are separated by centrifugation at 5000 x g for 45 minutes. The supernatant is discarded and the precipitates re-dissolved in 30ml of 50 mM MES buffer containing 100 mM NaCl, pH 6.5.
Example 7: Purification of polysaccharide-protein conjugate by Tangential flow filtration (TFF).
The conjugate sample after ammonium sulphate purification is further purified by using 300 kDa MWCO cassettes from Pall. This step ensures the removal of free protein if any from the conjugate and to separate free PS further from the conjugated PS. The conjugate is diafiltered with 20 X volume of MES buffer, pH 6.5 and finally concentrated to a volume of 35 ml.
Hence the removal of residual reagents used during the entire conjugation process is ensured at four different steps, first for PS: at the time of activated PS precipitation step, second for carrier protein: at the GPC purification step, third for whole conjugation process: by Ammonium sulphate precipitation and fourth: by 300kDa diafilteration step. It is further filtered by 0.2μ filters finally and stored at 2-8°C.
Example 8: Characterization of MenX-TT conjugate:
The purified conjugate is analyzed for total polysaccharide content by phosphorous assay for MenX-TT conjugates. Protein content is determined by Lowry's assay. The free polysaccharide determined by precipitating with sodium deoxycholate method and supernatant is analyzed by respective colorimetric assay. Different assays to determine the various
WO 2017/158480
PCT/IB2017/051408 residuals are conducted before using it further for formulation. The purified conjugates are stored at 2 - 8 °C.
The Conjugates of the present invention when analyzed for various 5 Quality parameters (Table 3) and found to give polysaccharide/protein ratio in the range of 0.3 - 0.7 (w/w). Amount of free polysaccharide is different for different conjugates, however, over all free polysaccharide has been less than 10% in purified conjugates. Conjugation yield has also varied for different conjugates from 18% to 43%. In this invention, various conjugation scales are tried from 20mg to 230mg.
Table 3: Characterization of different Men X-TT conjugate lots
| Conjugate Lot No. | PS taken !!!!!!lfclllllll conjugation | Total PS in final conjugate | Total Protein in final conjugate | PS:Protein ratio in purified conjugate (w/w) | Free PS in purified conjugate | Conjug- ation Yield |
| 1 | 35mg | 11.6mg | 29.8mg | 0.389 | 2.5% | 31% |
| 2 | 20mg | 3.7mg | 7.2mg | 0.512 | 7.0% | 19% |
| 3 | 24mg | 7.0mg | 11.43mg | 0.612 | 9.7% | 29% |
| 4 | 22mg | 8.9mg | 25mg | 0.356 | 1.1% | 40% |
| 5 | lOOmg | 18.4mg | 27.6mg | 0.666 | <1.0 % | 18 % |
| 6 | 230mg | 43mg | 120mg | 0.357 | <1.0 % | 19% |
| 7 | 200mg | 69mg | 105mg | 0.657 | 4.0% | 35% |
| 8 | 200mg | 85mg | 170mg | 0.500 | 1.8% | 43% |
| AVERAGE | 0.506 | 3.5% | 29.3% |
WO 2017/158480
PCT/IB2017/051408
Example 9: Characterization of Men A, C, Y, W conjugates obtained by carbamate chemistry
In a similar way to MenX, the serogroups Men A, C, Y & W conjugates were prepared by using the present invention. All the conjugates were characterized for various Quality parameters and found to give the desired results (Table 4).
Table 4: Characterization of different Men-TT conjugates
| Conjugate type (Men-TT) | PS taken for conjugation | Total PS in final conjugate | Total Protein in final conjugate | PS:Protein ratio in purified conjugate (w/w) | Free PS in purified conjugate | Conjug- ation yield |
| Men A-TT | 20mg | 5.6mg | 13.6mg | 0.412 | 4.5% | 28% |
| Men C-TT | 40mg | 9.7mg | 27.1mg | 0.358 | 6.0% | 24% |
| Men Y-TT | 25mg | 8.2mg | 20.3mg | 0.404 | 2.7% | 33% |
| MenW-TT | 30mg | lO.lmg | 24.2mg | 0.417 | 4.1% | 34% |
Example 10: Stability of MenX-TT conjugate:
The Conjugates of the present invention are exposed to high temperature conditions of 37°C for 28 days. The samples have been taken out on day 7,14,21 & 28 to monitor the free polysaccharide generated. The stability of the Men X conjugates, prepared by the defined Carbamate chemistry in this embodiment, proved the process applicability to generate extreme stable conjugates (Table 5).
WO 2017/158480
PCT/IB2017/051408
Table 5: Stability data for Men X-TT conjugate lot, prepared by the chemistry of present invention
| Carbamate Conjugate type | Free PS iii/ioiii initial point | iiiiiiiei lllllllllll after 7 days | ||Ι1111|1|| llllllliilllll after 14 | Free PS % at 37°C after 21 days | lllllillllil lllllllllll after 28 IlllllSilllii |
| Men X-TT Conjugate Loti | < 1.0% | < 1.0% | < 1.0% | < 1.0% | < 3.0% |
| Men X-TT Conjugate Lot 2 | 4.0% | 7.5% | 7.6% | 9.0% | 10.5% |
| Men X-TT Conjugate Lot 3 | 1.8% | 2.1% | 3.4% | 3.5% | 4.0% |
Example 11: Immunogenicity of MenX Conjugates
Groups of 8 female BALB/c mice of 5-9 weeks have been immunized on days 0, 14 and 28 with two different lots of MenX conjugated PS antigen formulated in normal saline (Table 6) at 1 pg dose level. All immunizations are performed by administering 200 μΐ of vaccine dilution via subcutaneous route. Normal saline alone is used for negative control group. Sera is collected at 7-14 days after 2 and 3-doses. Specific anti-PS IgG antibody titers are estimated by ELISA for post 2 and 3-dose.
The maximum IgG titers for MenX conjugates are achieved after two boosters. It is observed that for MenX the increase in titer value after 3 doses, in comparison to negative control is approximately 100 fold in Men
WO 2017/158480
PCT/IB2017/051408
X conjugate lot 1 and 150 fold in Men X conjugate lot 2 (Table 6).
Table 6: Geometric mean for IgG titer by ELISA post 2- and 3-dose (+,- 95% Confidence Interval for post 3-dose) for MenX-TT formulations in mouse model, after immunization with lgg of antigen on day 0,14 and 28.
| Geometric mean for IgG titer bv ELISA | |||
| Days | Vehicle Control llllHIIIII | 1 pg Men X - TT Lot 1 conjugate iiiiBiiiiiiiiii | 1 Mg Men X - TT Lot 2 conjugate |
| Post 2-dose (Pooled sera analysis) | 196 | 30338 | 30946 |
| Post 3-dose (Individual sera analysis) | 261(405,169) | 25293 (32112,19922) | 38224 (48928,29862) |
Example 12: Serum Bactericidal Assay (SBA) for MenX Conjugates Equal volume from each of the sera sample belonging to a group of mice are pooled together to make group sera pools for testing by serum bactericidal assay. The assay is performed as follows:
Streak the N. meningitidis serogroup X target strain for single colony isolation and incubate overnight at 37°C with 5% CO2 on a Sheep blood agar plate. The strain is subcultured by spreading cells over the entire surface of another Sheep Blood agar plate and then incubated for fresh growth at 37°C with 5% CO2. Bacteria are resuspended in ~ 5 ml of bactericidal assay buffer. Suspension ODeso is being adjusted equivalent colony count of approximately lx 105 cfu/ml. The sera are diluted serially 2-fold and assay buffer is added in control wells. 10μ1 of the working solution of bacteria is added to every well. 10 μΐ of heat inactivated (kept at
WO 2017/158480
PCT/IB2017/051408
56°C for 30 min.) complement is added to all inactive complement control wells and 10 μΐ of said inactivated complement is added to sera containing wells and active complement control wells. Shake the plates and incubate the plates for 1 hour at 37°C.
After incubation, spot 10gL from each wells on slanted blood agar plate. Incubate all agar plates for overnight at 37°C with 5% CO2. Count the number of colonies on each spot of the plates. The highest serum dilution showing >50% killing of bacteria as compared to complement control is considered as the SB A titre of that serum sample.
The SBA data shows a negligible response from the vehicle immunizations after 3 doses, whereas both the Men X conjugate lots under test showed significantly high SBA titres as compared to the vehicle control indicating the vaccine to be effective in-vivo in the mouse model (Table 7).
Table 7: Geometric mean titer for SBA post 2- and 3-doses (+,- 95% Confidence Interval for post 3-doses) for MenX-TT formulations in mouse model, after immunization with lgg of antigen on day 0,14 and 28.
| Geometric mean titer for SBA | |||
| Days | Vehicle Control llllllllllll | 1 Mg MenX-TT Lot 1 conjugate ||^||||·|||||||||| | 1 Mg Men X - TT Lot 2 conjugate |
| Post 2-dose (Pooled sera analysis) | 2 | 64 | 256 |
| Post 3-dose (Individual sera analysis) | 2 (2,2) | 235 (686,80) | 395 (564,276) |
2017/158480
PCT/IB2017/051408
Claims (26)
- We claim1. Novel polysaccharide-protein conjugates with high immunogenicity, wherein said polysaccharide-protein conjugates comprises of- at least one polysaccharide obtained from group of gram negative bacteria including but not limited to Haemophilus influenzae type b (Hib), Neisseria meningitidis (Men), Streptococcus pneumoniae;- at least one carrier protein wherein- said polysaccharide-protein conjugates have stable carbamate linkage -O- (C=O)-N-,- the formula of said conjugates is PS-L1-L2-CR wherein PS is polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is carrier protein.
- 2. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said polysaccharide is preferably Neisseria meningitides capsular polysaccharide, more preferably Neisseria meningitides capsular polysaccharide of serogroup A, C, Y, W or X.
- 3. The novel polysaccharide-protein conjugates as claimed in claim 2 wherein said polysaccharide is Neisseria meningitidis capsular polysaccharide of serogroup X.
- 4. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said carrier protein is selected from, but not limited to, TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles).2017/158480PCT/IB2017/051408
- 5. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said conjugates are stable and capable of being used as a vaccine candidate either alone or in combination.
- 6. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said conjugates are stable at room temperatures.
- 7. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said conjugates have free polysaccharide increment of less than 10.5% when stored at 37°C for 28 days.
- 8. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said high immunogenicity of said conjugates ranges from 100 fold to 150 fold increase in titer value after three doses in comparison to negative control.
- 9. The novel polysaccharide-protein conjugates as claimed in claim 1 wherein said conjugates shows Serum Bactericidal Assay Titres in the range from 32 fold to 128 fold after two doses and 118 fold to 198 fold after three doses in comparison to vehicle control.
- 10. A process to obtain novel polysaccharide-protein conjugates with high immunogenicity, said process comprising the steps of (a) degrading said at least one capsular polysaccharide to an optimum size range, (b) dissolving said degraded polysaccharide of step (a) in strong electrolytic salts and allowing proper mixing of resultant2017/158480PCT/IB2017/051408 mixture for predetermined period of time wherein said predetermined period of time ranges from 30 min to 90 min, (c) removing moisture from the resultant mixture obtained in the step (b) by known techniques including but not limited to lyophilization, rotary evaporation or vacuum drying to obtain dried polysaccharide, (d) dissolving said dried polysaccharide of step (c) in at least one non- aqueous aprotic solvents, (e) reacting the resultant solution of step (d) with pre-determined concentration of at least one moisture free activating agent, (f) keeping the resultant mixture of step (e) for a pre-determined period to obtain polysaccharide with at least one linker which is a activated polysaccharide wherein said predetermined period ranges from 2 hours to 3 hours, (g) purifying said activated polysaccharide of step (f) by known methods including but not limited to ammonium sulphate precipitation, diafiltration, size exclusion chromatography and/ or a combination thereof, (h) reacting said purified activated polysaccharide of step (g) with at least one activated carrier protein having at least one in-built linker for a predetermined period of time at broad pH range wherein said predetermined period of time ranges from 2 hours to 20 hours.
- 11. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said optimum size range of said2017/158480PCT/IB2017/051408 degraded polysaccharide ranges from distribution coefficient of 0.38+0.06 kD.
- 12. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said non-aqueous aprotic solvents are selected from, but not limited to, anhydrous Dimethyl sulfoxide (DMSO), Dimethyl formamide (DMF), N-Methyl pyrrolidone (NMP) or Dimethyl Acetamide.
- 13. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said at least one moisture free activating agent is Ν,Ν'-Carbonyl Di imidazole (CDI), N,NDisuccinimidyl carbonate (DSC) or Ν,Ν'-Disuccinimidyl oxalate (DSO).
- 14. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said at least one activated carrier protein is selected from, but not limited to, TT (tetanus toxoid), DT (Diphtheria toxoid), CRM197 (non-toxic mutant of DT), OMPV (Outer membrane protein vesicles).
- 15. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said pre-determined concentration of at least one moisture free activating agent ranges from 5 to 50 molar excess, preferably 30 molar excess.2017/158480PCT/IB2017/051408
- 16. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said broad pH range is from pH 6 to pH 10.
- 17. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said polysaccharide-protein conjugates have stable carbamate linkage -O- (C=O)-N
- 18. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said process yields conjugates of formula PS-L1-L2-CR wherein PS is polysaccharide, LI is a carbamate linkage, L2 is a hydrazide linkage and CR is carrier protein.
- 19. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said at least one linker on the activated polysaccharide is carbamate.
- 20. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said at least one linker on the activated carrier protein is hydrazide.
- 21. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein said degraded and activated polysaccharide and said activated carrier protein are mixed in a proportion ranging from 0.5:1 to 1:0.5 w/w, more preferably 1:1 w/ w in a buffer of pH 7.0-10.0 preferably pH 9.0.WO 2017/158480PCT/IB2017/051408
- 22. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 21 wherein said buffer is selected from but not limited to carbonate buffer, borate buffer.5
- 23. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein polysaccharide/protein ratio in said conjugate ranges from 0.3 to 1.0 (w/w).
- 24. The process to obtain novel polysaccharide-protein conjugates as10 claimed in claim 10 wherein said conjugates have free polysaccharide less than 10% in purified conjugates.
- 25. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein yield of conjugate obtained by said15 conjugation process is up to 60%.
- 26. The process to obtain novel polysaccharide-protein conjugates as claimed in claim 10 wherein average yield of conjugate obtained by said conjugation process is 30±5%.WO 2017/158480PCT/IB2017/0514081/6Cr1: Protein with carboxylate group 2; EDAC 3: Acvlisourea reactive ester 4: Linker with terminal amine 5: Amide bond 6: UreaFig-1WO 2017/158480PCT/IB2017/0514082/6Fig-3WO 2017/158480PCT/IB2017/0514087.003/66 005.00·A Men X Polysaccharide-1 hr degradation Native Purified Men X Polysaccharide^ / \2hr degradation4 003 002.00·1.00·0 00-1.00·1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00MinutesFig· 4WO 2017/158480PCT/IB2017/0514084/6Fig. 5Fig. 6WO 2017/158480PCT/IB2017/0514085/6Fig-7WO 2017/158480PCT/IB2017/0514086/6SSisSFig. 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611008901 | 2016-03-15 | ||
| IN201611008901 | 2016-03-15 | ||
| PCT/IB2017/051408 WO2017158480A1 (en) | 2016-03-15 | 2017-03-10 | Novel polysaccharide-protein conjugates and process to obtain thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017234319A1 true AU2017234319A1 (en) | 2018-09-27 |
| AU2017234319B2 AU2017234319B2 (en) | 2021-11-04 |
Family
ID=59851687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017234319A Expired - Fee Related AU2017234319B2 (en) | 2016-03-15 | 2017-03-10 | Novel polysaccharide-protein conjugates and process to obtain thereof |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2019508468A (en) |
| KR (1) | KR102428253B1 (en) |
| CN (1) | CN108883192A (en) |
| AU (1) | AU2017234319B2 (en) |
| BR (1) | BR112018068523A2 (en) |
| MX (1) | MX2018010920A (en) |
| MY (1) | MY199399A (en) |
| RU (1) | RU2758090C2 (en) |
| WO (1) | WO2017158480A1 (en) |
| ZA (1) | ZA201806043B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102692762B1 (en) | 2016-09-02 | 2024-08-08 | 사노피 파스퇴르 인크 | Neisseria meningitidis vaccine |
| WO2019003238A1 (en) * | 2017-06-27 | 2019-01-03 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel multivalent polysaccharide – protein conjugate vaccine composition and formulation thereof |
| CN110652585B (en) * | 2018-10-26 | 2023-05-26 | 武汉博沃生物科技有限公司 | Polysaccharide-protein conjugate immune preparation and application thereof |
| CN110302375A (en) * | 2019-06-27 | 2019-10-08 | 康希诺生物股份公司 | A kind of glycoconjugate and use thereof |
| RU2770877C1 (en) * | 2021-04-08 | 2022-04-22 | Федеральное бюджетное учреждение науки "Ростовский научно-исследовательский институт микробиологии и паразитологии" | Method of producing antigenic conjugated substance of haemophilic type b microbe for creating vaccine preparations |
| CN114965784B (en) * | 2022-06-01 | 2023-10-27 | 艾美探索者生命科学研发有限公司 | Method for measuring polysaccharide activation degree |
| CN116087363B (en) * | 2023-02-15 | 2025-03-14 | 北京生物制品研究所有限责任公司 | A method for detecting the content of carboxymethyl dextran in adsorption vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
| RU2233172C2 (en) * | 1997-07-17 | 2004-07-27 | Бакстэ Хелскеа С.А. | Haemophilus influenzae immunogenic conjugate polysaccharide - porin of meningococcus group b (variants), method for its preparing, pharmaceutical composition and method for immune response induction in animal with regards to haemophilus influenzae |
| GB0220198D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
| PE20070163A1 (en) * | 2005-06-27 | 2007-03-01 | Glaxosmithkline Biolog Sa | IMMUNOGENIC COMPOSITION OF CONJUGATES OF N. MENINGITIDIS PRIESTS |
| CN1709505B (en) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | Multivalent Bacterial Capsular Polysaccharide-Protein Conjugate Vaccine |
| BRPI1011753B8 (en) * | 2009-06-22 | 2021-05-25 | Wyeth Llc | immunogenic conjugates of capsular polysaccharide from staphylococcus aureus serotypes 5 and 8, their use and compositions comprising them |
| US9198977B2 (en) * | 2012-01-30 | 2015-12-01 | Serum Institute Of India Ltd. | Immunogenic composition |
| EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
-
2017
- 2017-03-10 MX MX2018010920A patent/MX2018010920A/en unknown
- 2017-03-10 BR BR112018068523A patent/BR112018068523A2/en not_active IP Right Cessation
- 2017-03-10 JP JP2018548790A patent/JP2019508468A/en active Pending
- 2017-03-10 KR KR1020187027889A patent/KR102428253B1/en active Active
- 2017-03-10 CN CN201780017800.6A patent/CN108883192A/en active Pending
- 2017-03-10 MY MYPI2018703258A patent/MY199399A/en unknown
- 2017-03-10 WO PCT/IB2017/051408 patent/WO2017158480A1/en not_active Ceased
- 2017-03-10 RU RU2018135066A patent/RU2758090C2/en active
- 2017-03-10 AU AU2017234319A patent/AU2017234319B2/en not_active Expired - Fee Related
-
2018
- 2018-09-10 ZA ZA2018/06043A patent/ZA201806043B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017158480A1 (en) | 2017-09-21 |
| ZA201806043B (en) | 2019-05-29 |
| RU2758090C2 (en) | 2021-10-26 |
| RU2018135066A (en) | 2020-04-06 |
| BR112018068523A2 (en) | 2019-01-22 |
| AU2017234319B2 (en) | 2021-11-04 |
| MY199399A (en) | 2023-10-25 |
| KR20180121564A (en) | 2018-11-07 |
| RU2018135066A3 (en) | 2020-11-10 |
| JP2019508468A (en) | 2019-03-28 |
| KR102428253B1 (en) | 2022-08-02 |
| MX2018010920A (en) | 2019-03-06 |
| CN108883192A (en) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017234319B2 (en) | Novel polysaccharide-protein conjugates and process to obtain thereof | |
| JP5361767B2 (en) | Modified sugars with improved stability in water | |
| CN111065387B (en) | Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates | |
| ES2658851T3 (en) | Protein matrix vaccines and methods of preparation and administration of such vaccines | |
| RU2634405C2 (en) | Immunogenic composition | |
| TW201925458A (en) | Composition comprising Streptococcus pneumoniae polysaccharide-protein conjugate and method of use thereof | |
| CN117736348A (en) | Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates | |
| WO2015144031A1 (en) | Pneumococcus polysaccharide protein conjugated vaccine and preparation method therefor | |
| CN119303072A (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| JP7100031B2 (en) | Immunogenic conjugates and their use | |
| ES2293002T5 (en) | Improved polysaccharide and glucoconjugate vaccines | |
| JP2019526573A (en) | Neisseria Meningitidis vaccine | |
| CN112741901A (en) | Vaccine containing streptococcus pneumoniae capsular polysaccharide type 5 and preparation method thereof | |
| US20110229513A1 (en) | LPS Based Vaccines | |
| JP4918356B2 (en) | Y group meningococcal vaccine and their meningococcal combination vaccine | |
| CN113271967A (en) | Multivalent glycoconjugate immunogenic compositions | |
| WO2025021710A1 (en) | Immunogenic composition | |
| WO2019198096A1 (en) | Tetravalent meningococcal vaccine composition and process to prepare thereof | |
| HK40059433A (en) | Multivalent glycoconjugates immunogenic compositions | |
| Pozsgay | Bacterial polysaccharide-protein conjugate | |
| HK1249403A1 (en) | Protein matrix vaccines and methods of making and administering such vac-cines | |
| HK1175689A (en) | Polysaccharide conjugation with detoxified e. coli heat labile enterotoxin (lt) used as vaccine | |
| HK1229726A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| HK1136220A (en) | Protein matrix vaccines and methods of making and administering such vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |